Skip to content
Search

Latest Stories

Government targets vape crackdown: Restrictions on sales, flavours, and retail display

The UK government has published a consultation following PM Rishi Sunak’s plans to create a ‘smoke-free generation’

At the Conservative Party Conference, PM Rishi Sunak pledged to raise the legal age every year to buy from those who were born in 2009.


The proposed changes also encompass heated tobacco products, recognized as smoke-free alternatives that heat, not burn, tobacco to produce a distinct nicotine-containing aerosol compared to traditional cigarette smoke.

The following move in a bid to “try and stop teenagers taking up cigarettes in the first place”, and bring in restrictions to stop young people from vaping.

PM Rishi Sunak spoke at the conference, “Last week I promised to create the first smoke-free generation and I am wasting no time to deliver on that promise.

“Our ambitious plans will reverse the worrying rise in youth vaping while protecting our children from the dangerous long-term effects of smoking as quickly as possible.”

While selling vapes to minors is already prohibited, recent data reveals a threefold increase in underage vaping over the past three years, with 20.5% of 11 to 17-year-olds having experimented with vaping in 2023, as reported by Action on Smoking and Health (ASH).

Mark Drakeford, the first minister said that he was “attracted” to Australia's policy of prohibiting the sale of vapes to pharmacies.

Instead, he said, “In Australia for example the only way you can get an e-cigarette is by prescription. You can't buy them in shops.

“Only through a medical prescription as part of a supervised attempt to give up smoking are they available.

“And do you know, I would be attracted to that idea myself.”

However, there are pharmacists who run smoking cessation clinics and some sell vaping products.

Regarding the limitations on vape sales, Professor Claire Anderson, RPS President, remarked: “The Royal Pharmaceutical Society agrees that the advertising and marketing for sweet, disposable, flavoured e-cigarettes should be restricted in the same way as tobacco products to reduce the appeal to young people who have never smoked to start using e-cigarettes.

“Better enforcement of the age of sale regulations for e-cigarettes is also needed to prevent illegal use by those under 18 years old to prevent them from becoming addicted to nicotine at an early age.

“E-cigarettes are one of several harm reduction options for short-term use to encourage smokers to stop using tobacco products.

“They should be accessible to adults who smoke and wish to stop, but it’s important that people are advised of all the smoking cessation options available to them for the greatest chance of success.

“Local pharmacists regularly advise the public about how to stop smoking. The ultimate aim should be to support people to stop using e-cigarettes and to be free of nicotine addiction altogether.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less